Tumor necrosis factor (TNF) enhances the locomotion of low-density human tonsillar B lymphocytes through the selective triggering of type II receptor.
Corcione
A
A
Laboratory of Oncology, Scientific Institute G. Gaslini, Genova, Italy.
Ottonello
L
L
Tortolina
G
G
Tasso
P
P
Ghiotto
F
F
Airoldi
I
I
D'Agostino
R
R
Dallegri
F
F
Pistoia
V
V
D000251:Adenosine Triphosphatases; D015703:Antigens, CD / Q000378:metabolism; D001081:Apyrase; D001402:B-Lymphocytes / Q000166:cytology*; D002465:Cell Movement / Q000187:drug effects*; D005434:Flow Cytometry; D006801:Humans; D007072:Immunoglobulin D / Q000378:metabolism; D014066:Palatine Tonsil / Q000166:cytology*; D018124:Receptors, Tumor Necrosis Factor / Q000378:metabolism*; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology*
D015703:Antigens, CD; D007072:Immunoglobulin D; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000251:Adenosine Triphosphatases; D001081:Apyrase; C067869:CD39 antigen